• Vaccine Name: C. jejuni MBP-FlaA protein vaccine
• Target Pathogen: Campylobacter jejuni
• Target Disease: Campylobacterosis
• Vaccine Ontology ID: VO_0011493
• Type: Subunit vaccine
• Status: Research
• Antigen: C. jejuni structural flagella protein flaA and maltose-binding protein MBP
• FlaA from C. jejuni 81-176 gene engineering:
  • Type: Recombinant protein preparation
  • Description: Purification schemes were essentially as recommended by NEB. DH5α containing the flagellin-MBP fusion was grown overnight in 10 ml of rich medium (10 g of tryptone, 5 g of yeast extract, 5 g of NaCl, and 2 g of glucose/liter) supplemented with 100 μg of ampicillin per ml and used to inoculate a fresh 1-liter culture of the same medium. This culture was grown with shaking at 37°C to an optical density at 600 nm of 0.5, and IPTG (isopropyl-β-d-thiogalactoside; Gibco, Gaithersburg, Md.) was added to a final concentration of 0.3 mM (Lee et al., 1999).
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001321
  • Description: Mutant E. coli heat-labile enterotoxin (LT(R192G)) (Lee et al., 1999)
• Immunization Route: Intranasal

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Mice were anesthetized with methoxyflurane (Metofane; Pitman-Moore, Mundelein, Ill.) and immunized intranasally with 30 to 35 μl of fusion protein by using a micropipette. The doses used were 0, 3, 6, 12, 25, or 50 μg of fusion protein in phosphate-buffered saline (PBS), either alone or in combination with 5 μg of the genetically modified heat-labile enterotoxin of E. coli, designated LTR192G as an adjuvant. A second dose was administered 8 days after the first vaccination (Lee et al., 1999).
• Challenge Protocol: Mice were intranasally challenged with 2 × 10^9 C. jejuni bacteria/mouse 26 days after the second vaccination, and the animals were monitored for sickness and death for 5 days (Lee et al., 1999).
• Efficacy: The protective efficacies of a 50 microgram of MBP-FlaA plus LT(R192G) dose against disease symptoms and intestinal colonization were 81.1 and 84%, respectively. When mice which had been immunized with 50 microgram of MBP-FlaA plus LT(R192G) intranasally were challenged orally with 8 x 10^10, 8 x 10^9, or 8 x 10^8 cells of strain 81-176, the protective efficacies against intestinal colonization at 7 days postinfection were 71.4, 71.4, and 100%, respectively (Lee et al., 1999).
• Host IgA response
  • Description: Stimulation of FlaA-specific intestinal secretory IgA (sIgA) responses required immunization with higher doses of MBP-FlaA (>/=25 microgram) or coadministration of lower doses with the adjuvant. IgA titers were significant 7 days after immunization as compared to PBS-vaccinated mice (Lee et al., 1999).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: The full range of MBP-FlaA doses were effective in eliciting significant antigen-specific serum immunoglobulin G (IgG) responses, and these responses were enhanced by adjuvant use, except in the highest dosing group. The results were compared to PBS vaccinated mice 7 days after immunization (Lee et al., 1999).
  • Detailed Gene Information: Click Here.